Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sionna Therapeutics, Inc. - Common Stock (NQ:SION)

35.20 -0.44 (-1.22%)
Streaming Delayed Price Updated: 1:52 PM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 128,666
Open 35.55
Bid (Size) 35.02 (100)
Ask (Size) 35.39 (200)
Prev. Close 35.64
Today's Range 32.40 - 35.55
52wk Range 7.255 - 43.20
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sionna Therapeutics Reports Third Quarter 2025 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics to Participate in Upcoming November Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+40.8%
+40.8%
1 Month
+20.4%
+20.4%
3 Month
+100.8%
+100.8%
6 Month
+175.9%
+175.9%
1 Year
+40.8%
+40.8%

More News

Read More
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Sionna Short Squeeze Fades As Raymond James Backs Cystic Fibrosis Breakthrough, RBC Warns Treatments Set High Bar
Via Stocktwits
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics Reports Second Quarter 2025 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Hut 8, Greenbrier And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial
Via Benzinga
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics Reports First Quarter 2025 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025
From Sionna Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Alcoa Posts Weak Revenue, Joins QXO And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Liberty Energy Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
AI Mobility Provider, Steel Veteran Made Trading Debuts
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Sionna Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Sionna Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sionna Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sionna Therapeutics, Inc. - Common Stock trade on?
Sionna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sionna Therapeutics, Inc. - Common Stock?
The ticker symbol for Sionna Therapeutics, Inc. - Common Stock is SION on the Nasdaq Stock Market
What is the current price of Sionna Therapeutics, Inc. - Common Stock?
The current price of Sionna Therapeutics, Inc. - Common Stock is 35.20
When was Sionna Therapeutics, Inc. - Common Stock last traded?
The last trade of Sionna Therapeutics, Inc. - Common Stock was at 11/05/25 01:52 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.